ArticleTransfusion2017
Comparative analyses of industrial-scale human platelet lysate preparations.
Article in Transfusion, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Systematic review and meta-analysis on the use of human platelet lysate for mesenchymal stem cell cultures: comparison with fetal bovine serum and considerations on the production protocol.Stem cell research & therapy · 2022Pooled it
- Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review.Journal of translational medicine · 2020Pooled it
- Human platelet lysate standardization across three independent European blood establishments.Stem cell research & therapy · 2025Article
- Animal origins free products in cell culture media: a new frontier.Cytotechnology · 2025Review
- In vitro regenerative effects of a pooled pathogen-reduced lyophilized human cord blood platelet lysate for wound healing applications.Blood transfusion = Trasfusione del sangue · 2024Article
- Comparison between Platelet Lysate, Platelet Lysate Serum, and Fetal Bovine Serum as Supplements for Cell Culture, Expansion, and Cryopreservation.Biomedicines · 2024Article
- Risks in Induction of Platelet Aggregation and Enhanced Blood Clot Formation in Platelet Lysate Therapy: A Pilot Study.Journal of clinical medicine · 2022Article
- Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.International journal of molecular sciences · 2021Review
- Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells.Cells · 2021Review
- Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.Frontiers in cell and developmental biology · 2021Review
- Platelet lysate for COVID-19 pneumonia-a newer adjunctive therapeutic avenue.Stem cell investigation · 2021Review
- Chitosan hydrogel incorporated with dental pulp stem cell-derived exosomes alleviates periodontitis in mice via a macrophage-dependent mechanism.Bioactive materials · 2020Article
- Article
- Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells.Blood research · 2020Article
- Upregulation of mitotic bookmarking factors during enhanced proliferation of human stromal cells in human platelet lysate.Journal of translational medicine · 2019Article
- Blood Plasma Derivatives for Tissue Engineering and Regenerative Medicine Therapies.Tissue engineering. Part B, Reviews · 2018Review
- The clinical efficacy of using autologous platelet-rich plasma in total hip arthroplasty: A retrospective comparative study.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEfforts are underway to eliminate fetal bovine serum from mammalian cell cultures for clinical use. An emerging, viable replacement option for fetal bovine serum is human platelet lysate (PL) as either a plasma-based or serum-based product. STUDY DESIGN AND
methodsNine industrial-scale, serum-based PL manufacturing runs (i.e., lots) were performed, consisting of an average ± standard deviation volume of 24.6 ± 2.2 liters of pooled, platelet-rich plasma units that were obtained from apheresis donors. Manufactured lots were compared by evaluating various biochemical and functional test results. Comprehensive cytokine profiles of PL lots and product stability tests were performed. Global gene expression profiles of mesenchymal stromal cells (MSCs) cultured with plasma-based or serum-based PL were compared to MSCs cultured with fetal bovine serum.
resultsElectrolyte and protein levels were relatively consistent among all serum-based PL lots, with only slight variations in glucose and calcium levels. All nine lots were as good as or better than fetal bovine serum in expanding MSCs. Serum-based PL stored at -80°C remained stable over 2 years. Quantitative cytokine arrays showed similarities as well as dissimilarities in the proteins present in serum-based PL. Greater differences in MSC gene expression profiles were attributable to the starting cell source rather than with the use of either PL or fetal bovine serum as a culture supplement.
conclusionUsing a large-scale, standardized method, lot-to-lot variations were noted for industrial-scale preparations of serum-based PL products. However, all lots performed as well as or better than fetal bovine serum in supporting MSC growth. Together, these data indicate that off-the-shelf PL is a feasible substitute for fetal bovine serum in MSC cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.